Experimental vaccine aims to boost immune attack on colorectal cancer
NCT ID NCT06011772
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 40 times
Summary
This very early study tests whether adding the CIMAvax-EGF vaccine to standard treatment can help the immune system fight metastatic colorectal cancer. Only 2 patients with a specific gene type (RAS/BRAF wild-type) will receive the combination. The main goal is to see if the vaccine triggers a strong antibody response, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.